Literature DB >> 7578866

IgA antihistone antibodies in isoniazid-treated tuberculosis patients.

M Vázquez-Del Mercado1, C A Casiano, R L Rubin.   

Abstract

A retrospective study of tuberculosis patients treated with isoniazid was undertaken in order to establish the prevalence and specificity of antibodies against histones, chromatin and denatured DNA. Each patient had an average of 2.7 +/- 0.4 antibody activities out of the 8 tested antigens using ELISA. These reactivities tended to be higher for non-native forms of the antigens such as denatured histones and DNA with essentially no reactivity to the (H2A-H2B)-DNA subunit of chromatin. Greater than half of the patients were isotype restricted to only IgA or IgM antihistone antibodies, and IgA antihistone antibodies were the most common and reactive. Thirty-five percent of the patients had elevated levels of one or more immunoglobulin classes, and the IgA level was strongly correlated with IgA antihistone activity. These results suggest that isoniazid treatment results in modest increases in antihistone antibodies of the specificities and class typical of drug-induced autoimmunity in the absence of lupus-like disease. The IgA antihistone predominance suggests that serum antoantibodies may be the consequence of stimulation by isoniazid of lymphocytes in the gut-associated Peyer's patches or intestinal lymphoid follicles.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578866     DOI: 10.3109/08916939509001934

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  2 in total

Review 1.  Isoniazid in autoimmunity: a trigger for multiple sclerosis?

Authors:  Bardia Nourbakhsh; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2014-09       Impact factor: 6.570

Review 2.  Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions.

Authors:  R W Burlingame; R L Rubin
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.